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A new compound, euparvic acid (1,C 14H16O6), and the known compounds 5,7-dihydroxy-4-methylphthalide (2), 6-(3-
carboxybutyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-one (3), 6-(5-carboxy-3-methylpent-2-enyl)-7-hydroxy-5-meth-
oxy-4-methylphthalan-1-one (4), and 6-(5-carboxy-4-hydroxy-3-methylpent-2-enyl)-7-hydroxy-5-methoxy-4-methylphthalan-
1-one (5) were isolated from the EtOAc extract of Eupenicillium parVum. The structure of 1 was determined by
interpretation of MS and homo- and heteronuclear 2D NMR spectroscopic data and conﬁrmed by X-ray crystallography.
The absolute conﬁguration of 5 was determined via MPA ester derivatization.
Humate soil is organic matter that has a positive effect on the
physical, chemical, and biological reactions of the soil, leading to
an increase in soil fertility.
1 Humate is comprised of humic acid,
fulvic acid, some minerals, bacteria, and fungi, which facilitate the
development of deep root systems, enhance beneﬁcial microbial
activity, and improve overall plant health and resistance to diseases.
2
Continuing our earlier studies
3,4 on sourcing fungi for bioactive
natural products, we have investigated the constituents of Eupeni-
cillium parVum, isolated from a humate sample. Four known
derivatives (2-5) of the antibiotic mycophenolic acid (MPA),
previously isolated from the fermentation broths of several Peni-
cillium species, and a new derivative (1) were found. Mycophenolic
acid (4,C 17H20O6) is a potent inhibitor of human inosine 50-
monophosphate dehydrogenase (IMPDH), a key enzyme in the de
noVo biosynthesis of guanine nucleotide. Its prodrug, mycophenolate
mofetil (MMF), is used as an immunosuppressive agent to prevent
kidney allograft rejection. MPA has also been shown to possess
cytotoxicity against cancer cell lines.
5
We describe herein the isolation of ﬁve compounds (1-5) that
were separated by column chromatography, Sephadex LH-20, and
preparative TLC methods. While compound 1 is new, four




7 as a minor product, and 6-(5-carboxy-4-hydroxy-3-
methylpent-2-enyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-
one (5).
8 The 1H and 13C NMR (Table 1) spectroscopic data of 3
are reported for the ﬁrst time. The structure of 5,7-dihydroxy-4-
methylphthalide (2) was conﬁrmed by comparison of its spectro-
scopic data (MS, 1H and 13C NMR) with a literature reference.
9
Compound 1 was characterized as 6-(3-carboxybutyl)-5,7-
dihydroxy-4-methylphthalan-1-one, and the structure was deter-
mined on the basis of its MS and homo- (Table 1) and heteronuclear
2D NMR spectroscopic data and by X-ray crystallography.
Compound 1, a white crystalline solid, mp 175-176 °C, showed
a hydroxyl (3413 cm-1) and a ketone group (1698 cm-1) in the IR
spectrum. The ESIQTOFMS yielded a parent mass at m/z 263.0919
corresponding to the pseudomolecular ion [M - OH]+ (calcd
C14H15O5, m/z 263.0919). The 1H NMR spectrum of 1 (Table 1)
exhibited signals for a secondary methyl group at δ 1.18 (3H, d, J
) 6.8 Hz), an aromatic methyl group at δ 2.10, and a singlet signal
at δ 5.24 (2H) corresponding to an aliphatic methylene bearing
oxygen. These data were closely comparable to those of the known
compound 5,7-dihydroxy-4-methylphtalide (2)
9 and suggested that
compound 1 contains this nucleus in its structure. The 13C NMR
(Table 1) and DEPT spectra of 1 disclosed 14 carbons, which were
indicative of a saturated carboxylic acid at δ 179.3 (C-5′ ), two
aliphatic methylenes at δ 20.6, and 33.0, an aliphatic methine at δ
38.9, and a secondary methyl group at δ 17.0, and suggested a
chain in the position C-6 of the nucleus, in which the 1H-1H-COSY
experiment allowed the sequential assignment. On the basis of the
above data, 1 was identiﬁed as a derivative of mycophenolic acid,
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Table 1. 1H-13C NMR (δ, J in Hz in parentheses) Data
a of







1 172.5 s 171.9 s
3 5.24 s 69.3 t 5.31 s 69.6 t
3a 144.8 s 145.3 s
4 110.3 s 116.7 s
5 161.1 s 163.6 s
6 114.8 s 122.3 s
7 153.3 s 153.5 s
7a 102.1 s 106.4 s
1′ 2.82-2.85 m 20.6 t 2.75 dd 21.2 t
2.74-2.76 m (8.5)
2′ 1.81-1.83 m 33.0 t 1.92-1.96 m 33.3 t
1.65-1.68 m 1.65-1.72 m
3′ 2.41-2.44 m 38.9 d 2.47-2.54 m 39.0 d
4′ 1.18 d (6.8) 17.0 q 1.22 d (7.3) 16.5 q
5′ 179.3 s 176.9 s
CH3-Ar 2.10 s 10.5 q 2.18 s 10.6 q
OCH3 3.83 s 60.6 q
a Based on COSY, HSQC, HMBC, and ROESY experiments.
b Spectrum recorded in acetone-d6.
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droxy-4-methylphthalan-1-one (euparvic acid, 1). The HMQC and
HMBC spectra supported the structure assignments. Finally, the
postulated structure was further validated by a single-crystal X-ray
study (Figure 1).
With compound 3, both the 1H and 13C NMR (Table 1)
spectroscopic data are similar to those of 1, but one difference in
their 1H NMR spectra was noted. An additional signal at δ 3.67
suggests the presence of a methoxy group at C-5. The 13C (Table
1) and DEPT NMR spectra conﬁrmed this observation. The
structure was assigned and conﬁrmed using HMBC and ROESY
data. A literature search led to the identiﬁcation of this compound
as 6-(3-carboxybutyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-
one (3), isolated earlier from the fermentations of different fungi.
6
Compound 5 exhibited NMR data (see Experimental Section)
closely comparable to those of mycophenolic acid (4) (MPA),
10
except for the presence of a hydroxyl group attached to C-4′ ,
corresponding to the structure 6-(5-carboxy-4-hydroxy-3-methyl-
pent-2-enyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-one. How-
ever, the relative conﬁguration at that center (C-4′ ) was not reported.
The absolute stereochemistry was assigned for 5, using Riguera’s
method for the determination of the absolute stereochemistry of
secondary alcohols.
11 Thus, compound 5 was converted to a methyl
ester (6) with TMSCHN2, which also methylated the phenol group.
Then, the methyl ester was treated with DMAP, DCC, and (S)-
MPA reagent in dry CH2Cl2. The 1H NMR and COSY spectra of
the resulting MPA esters were recorded in acetonitrile-d3. Next,
solid anhydrous Ba(ClO4)2 was added to the NMR tube until
saturation and new 1H NMR and COSY spectra were recorded.
The chemical shifts before and after the addition of the barium
salt to the MPA ester of 6 are summarized in Table 2. As a result
of the addition of the barium salt, the more stable conformation
was favored and the NMR signals of the 5′ protons were shifted to
a lower ﬁeld (negative ∆δBa values). In contrast, protons 1′ ,2 ′ ,
and 7′ , which belong to the L1 group, were shifted to the higher
ﬁeld (∆δBa L1 > 0 and ∆δBa L2 < 0). On the basis of the
experimental results obtained, the S absolute conﬁguration was
assigned to C-4′ (Figure 2), so the structure of compound 5 was
established as 6-[(4S)-5-carboxy-4-hydroxy-3-methylpent-2-enyl]-
7-hydroxy-5-methoxy-4-methylphthalan-1-one.
Compounds 1-6 did not show activity in standard disk assays
against Escherichia coli (ATCC 35218), Pseudomonas aeruginosa
(ATCC 27853), methicillin-resistant Staphylococcus aureus (ATCC
43300), Mycobacterium intracellulare (ATCC 27853), or Aspergil-
lus fumigatus (ATCC 27853). Only compound 4 showed moderate
activity [IC50 µM: 8.0 and 15.0] against Candida albicans (ATCC
90028) and Cryptococcus neoformans (ATCC 90113), respectively.
Experimental Section
General Experimental Procedures. The melting point was deter-
mined on a Opti-Melt MPA 100 instrument (Stanford Research
Systems) and is uncorrected. Optical rotations were measured using a
Rudolph Research Analytical Autopol V polarimeter. IR spectra were
recorded using a Perkin-Elmer model spectrum-100 spectrophotometer.
1H and 13C NMR spectra were obtained on Bruker model AMX 500
and 400 NMR spectrometers with standard pulse sequences, operating
at 500 and 400 MHz in 1H and 125 and 100 MHz in 13C. Acetone-d6,
CD3OD, and CD3CN were used as solvents, and TMS was used as
internal standard. High-resolution mass spectra (HRMS) were recorded
on a Micromass Q-Tof Micro mass spectrometer with a lock spray
source. Column chromatography was carried out on silica gel (70-230
mesh, Merck). Fractions obtained from column chromatography were
monitored by TLC (silica gel 60 F254), and preparative TLC was carried
out on silica gel 60 PF254+366 plates (20 × 20 cm, 1 mm thick).
Fungal Material. The particular humate used was collected in Cuba,
NM, in March 2008 and was plated out on potato-dextrose agar (PDA)
that was maintained at 24 °C, until discrete fungal colonies appeared.
Samples were taken from colonies and kept on PDA slants in test tubes
at 24 °C, then placed in a 4 °C refrigerator until used. The fungus was
keyed to Eupenicillium parVum by comparison of its morphological
and DNA proﬁle data with the library in the National Centre for
Advanced Technologies, Lincoln University, New Zealand. A voucher
specimen (UM-042106) has been deposited in the culture collection
of the Medicinal Chemistry Department, University of Mississippi. The
fungus was inoculated in 50 mL of potato-dextrose broth and kept for
two weeks in stationary phase at 25 °C; then the mycelium and spore-
laden broth (1 mL) were seeded onto a medium in each ﬂask consisting
of 100 g of shredded wheat, 200 mL of low-pH Oxoid mycological
broth, 2% yeast extract, and 20% sucrose in 2.8 L Fernbach ﬂasks (22
ﬂasks) followed by incubation for 22 days at 24 °C.
Extraction and Isolation. Following incubation, 300 mL of acetone
was added to each ﬂask, and the mycelia and the substrate were
homogenized (Super Dispex, Tekmark Co., SD-45). The suspension
was ﬁltered and the ﬁltrate concentrated under a vacuum at <50 °C.
The residue was mixed with H2O (200 mL), then extracted with EtOAc
(500 mL × 3). The combined EtOAc extracts were dried over
anhydrous Na2SO4 and concentrated under a vacuum. The EtOAc
extract (7.0 g) was chromatographed on silica gel 60, 70-230 mesh
(400 g), with fractions stepwise eluted with CH2Cl2-Me2CO mixtures
(8:2; 7:3; 1:1), Me2CO, and Me2CO-MeOH (9:1) (each 200 mL),
yielding four fractions. Fraction 1 (150 mg) was rechromatographed
over silica gel, eluted with CHCl3-EtOAc (9:1), to yield 5,7-dihydroxy-
4-methylphtalide (2, 50 mg) and mycophenolic acid (3, 12 mg). Fraction
2 (200 mg) and fraction 3 (350 mg) were chromatographed over a silica
gel 60 column and eluted with a CHCl3-MeOH gradient to yield ﬁve
subfractions. Subfractions 3-5 were chromatographed by preparative
TLC with CHCl3-MeOH (19:1) three times, affording 6-(3-carboxy-
butyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-one (4, 10 mg) and
6-(3-carboxybutyl)-5,7-dihydroxy-4-methylphthalan-1-one (1, 8 mg).
From the last fraction, a solid was recovered and puriﬁed on a silica
gel column eluted with CHCl3-MeOH (50:1), followed by preparative
Figure 1. ORTEP-3 projection of compound 1, with the displace-
ment ellipsoids drawn at the 50% probability level. The atoms of
the minor component of the disorder in the molecule and the
hydrogens of both components have been omitted for clarity.
Table 2. 1H NMR Shifts of the MPA Ester of Compound 6
before and after the Addition of the Ba(ClO4)2 Salt
a
δH MPA ester δH MPA ester + Ba(ClO4)2 ∆δBa
1′ 3.293 3.192 +0.101
2′ 5.530 5.528 +0.002
4′ 5.241 5.166 +0.075
5′ 2.673 2.679 –0.006
7′ 1.612 1.528 +0.084
a 500 MHz, δ in ppm.
Figure 2. Ba2+ complex of the (S)-MPA ester of 6.
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3-methylpent-2-enyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-one (5,
30 mg).
Euparvic acid (1): colorless solid (MeOH-EtOAc); mp 175-176
°C; [R]20
D -4.0 (c 0.01, MeOH); IR (ﬁlm) νmax 3413, 2930, 1698, 1629,
1446, 1333, 1179, 1025, 932, 782 cm-1; 1H and 13C NMR, see Table
1; ESIQTOFMS m/z 280 (M+, absent), 263 (100), 235 (100); HRES-
ITOFMS m/z 263.0924 [M - OH]+ (calcd for C14H15O5, 263.0924),
235.0974 [M - CO2H]+ (calcd for C14H15O5, 235.0970).
X-ray Crystallographic Study of Euparvic Acid (1). A single-
crystal X-ray diffraction study was conducted on 6-(3-carboxybutyl)-
7-hydroxy-5-methoxy-4-methylphthalan-1-one (1). Colorless needles
were obtained with the slow evaporation of a solution in methanol.
A single crystal, approximate dimensions 0.15 × 0.09 × 0.05 mm,
was used for data collection on a Bruker Smart Apex II system,
12
using Cu KR radiation with a graphite monochromator, ﬁne-focus
sealed tube. The crystal was kept at 100 K under a stream of cooled
nitrogen gas from a KRYO-FLEX low-temperature device. Com-
pound 1,C 14H16O6,M W) 280.27, crystallizes in the monoclinic
space group P21/n, with one molecule in the asymmetric unit and
four molecules per unit cell (Z ) 4). Cell dimensions are a )
12.5306(8) Å, b ) 6.8656(3) Å, c ) 15.7783(9) Å,   ) 105.403(4)°,
V ) 1308.65(13) Å3. Data collection, indexing, and initial cell
reﬁnements were all carried out using APEX II software. All non-
hydrogen atoms were visible in the difference electron density maps.
Anisotropic displacement parameters were included in the reﬁnement
for all non-hydrogen atoms. Frame integration and ﬁnal cell
reﬁnements were done using SAINT software;
13 8451 reﬂexions
were read, with 397 rejected. The ﬁnal cell parameters were
determined from least-squares reﬁnement on 1822 reﬂections, with
Rint ) 0.050 and wR(F2) ) 0.084, and GooF ) 1.024. The maximum
resolution of the data collection was 0.85 Å. Most of the aliphatic
side chain, C9, C10, C11, C12, C13, O5, and O6, was disordered.
An attempt made to model disorder in this region during reﬁnement
allowed for the modeling of four disordered pairs, C10-C10a,
C11-C11a, C12-C12a, and O5-O5a. The average population ratio
of the disordered pairs was 0.413 to 0.587. In C9, C13, and O6, the
disordered pairs were too close to be separated after several
reﬁnement cycles and were left as large ellipsoids in the ﬁnal
projection.
Structure solution, reﬁnement, graphics, and generation of
publication materials were performed using SHELXTL, V6.12
software.
14 Hydrogen atoms were placed in their expected chemical
positions using the HFIX command and were included in the ﬁnal
cycles of least-squares reﬁnement, with isotropic Uij’s related to
the atoms ridden upon. The crystallographic data have been deposited
in the Cambridge Crystallographic Data Centre (deposition number
684326), and the data can be obtained free of charge from http://
www.ccdc.cam.ac.uk/deposit.
6-(3-Carboxybutyl)-7-hydroxy-5-methoxy-4-methylphthalan-1-
one (3): amorphous solid; [R]20
D -2.8 (c 0.01, MeOH); IR (ﬁlm)
νmax 3232, 2930, 1696, 1614, 1445, 1409, 1372, 1325, 1211, 1160,
1134, 1106, 1079, 1036, 962, 816, 795 cm-1; 1H and 13C NMR, see
Table 1; ESIQTOFMS m/z 317 (M + Na)+, 307 (20), 295 (25);
HRESITOFMS m/z 317.1006 [M + Na]+ (calcd for C15H18O6Na,
317.1001).
6-(5-Carboxy-4-hydroxy-3-methylpent-2-enyl)-7-hydroxy-5-meth-
oxy-4-methylphthalan-1-one (5): amorphous solid; IR (ﬁlm) νmax
3365, 2938, 2865, 1695, 1557, 1405, 1323, 1263, 1194, 1136, 1056,
1032, 970, 728 cm-1; 1H NMR (DMSO-d6, 500 MHz) δ 1.63 (3H,
s, CH3-7′ ), 1.97 (3H, s, CH3-Ar), 2.10 (2H, s br, H2-5′ ), 3.20 (2H,
d, J ) 5 Hz, H2-1′ ), 3.61 (3H, s, OCH3), 4.07 (1H, s br, H-4′ ), 5.13
(2H, s, H2-3), 5.37 (1H, dd, J ) 5.4 Hz, H-2′ ); 13C NMR (DMSO-
d6, 125 MHz) δ 11.5 (CH3--Ar), 12.5 (C-7′ ), 22.7 (C-1′ ), 43.0 (C-
5′ ), 60.6 (OCH3), 69.3 (C-3), 73.6 (C-4), 106.8 (C-7a), 110.0 (C-
4), 123.2 (C-2′ ), 124.2 (C-6), 136.2 (C-3′ ), 145.3 (C-3a), 153.0 (C-
7), 163.6 (C-5), 171.0 (C-1), 178.1 (C-6′ ); ESIQTOFMS m/z 359
(M + Na)+, 319 (60), 301 (40), 293 (20); HRESITOFMS m/z
359.1112 [M + Na]+ (calcd for C17H20O7Na, 359.1107).
Methyl Ester of 5 (6). To solution of 5 (3.0 mg) in CH2Cl2 (2.0
mL) was added excess TMSCHN2 (1 mL, 2.0 M), and the mixture
stirred at room temperature for 48 h. The reaction mixture was
concentrated under vacuum and puriﬁed by preparative TLC (silica
gel: benzene-EtOAc, 7:3) to furnish 3.0 mg of 6: 1H NMR (CDCl3,
500 MHz) δ 1.81 (3H, s, CH3-7′ ), 2.17 (3H, s, CH3-Ar), 2.53 (2H,
m, H2-5′ ), 3.43 (2H, d, J ) 3.4 Hz, H2-1′ ), 3.67 (3H, s, OCH3),
3.77 (3H, s, OCH3), 4.04 (3H, s, OCH3), 4.42 (1H, d, J ) 4.4 Hz,
H-4′ ), 5.13 (2H, s, H2-3), 5.49 (1H, dd, J ) 5.5 Hz, H-2′ ); 13C NMR
(CDCl3, 125 MHz) δ 11.5 (CH3-Ar), 12.15 (C-7′ ), 23.08 (C-1′ ),
39.98 (C-5′ ), 51.81 (OCH3), 61.04 (OCH3), 62.70 (OCH3), 68.37
(C-3), 73.16 (C-4′ ), 112.52 (C-7a), 119.98 (C-4), 124.94 (C-2′ ),
128.32 (C-6), 135.74 (C-3′ ), 146.91 (C-3a), 156.78 (C-7), 162.79
(C-5), 168.92 (C-1), 173.00 (C-6′ ); HRESITOFMS m/z 387.1422
[M + Na]+ (calcd for C19H24O7Na, 387.1420).
Preparation of the (S)-MPA Ester of Compound 6. A 2.0 mg
(0.0054 mmol) sample of the methyl ester 6 was treated with
(S)-methoxyphenylacetic acid (2.0 mg, 0.012 mmol), DCC (8.0 mg,
0.038 mmol), and DMAP (0.8 mg, 0.006 mmol) in DCM (10 mL) for
48 h at room temperature. The reaction mixture was worked up, and
the resulting MPA ester of 6 (0.7 mg) was dissolved in CD3CN for 1H
NMR measurements. HRESITOFMS: m/z 535.1948 [M + Na]+ (calcd
for C28H32O9Na, 535.1944).
Bioassays. Compounds 1 and 3-6 were tested against the
microorganisms Candida albicans, Cryptococcus neoformans, As-
pergillus fumigatus, methicillin-resistant Staphylococcus aureus,
Escherichia coli, Pseudomonas aeruginosa, and Mycobacterium
intracellulare. Amphotericin A was used as positive control for the
ﬁrst three microorganisms, and ciproﬂoxacin was used for the others.
Procedures for most of the antimicrobial susceptibility assays were
performed using a modiﬁed version of the NCCLS methods,
15 while
the susceptibility testing against the Mycobacterium was done using
the modiﬁed Alamar Blue procedure of Franzblau et al.
16 Samples
were dissolved in DMSO and were serially diluted using 0.9% saline.
These were transferred in duplicate to 96-well microplates. Plates
were read at either 630 nm or 544ex/590em (M. intracellulare) prior
to and after incubation. Percent growth was plotted versus test
concentration to afford the IC50.
While the biological activities in these systems are limited in scope,
attempts to isolate suitable quantities of euparvic acid will be performed
to test its effects in a broader range of bioassays.
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